Cost and cost-effectiveness of adjuvant trastuzumab in the real world setting: A study of the Southeast Netherlands Breast Cancer Consortium

BACKGROUND: We assessed the real world costs and cost-effectiveness of the addition of trastuzumab in HER2 positive early breast cancer compared to chemotherapy alone in the Dutch daily practice as opposed to the results based on trial data and based on a subset of patients that were treated accordi...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncotarget
Main Authors: Seferina, Shanly C., Ramaekers, Bram L.T., de Boer, Maaike, Dercksen, M. Wouter, van den Berkmortel, Franchette, van Kampen, Roel J.W., van de Wouw, Agnès J., Voogd, Adri C., Tjan Heijnen, Vivianne C.G., Joore, Manuela A.
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2017
Teme:
Clinical Research Paper
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5668034/
https://ncbi.nlm.nih.gov/pubmed/29108301
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.16985
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki